Filing Flows › Pharma-Bio Serv (PBSV) › Q2 FY25
Pharma-Bio Serv (PBSV) Q2 FY25 earnings results (second quarter fiscal 2025)
10-Q filed Jun 16, 2025
Pharma-Bio Serv (PBSV) reported revenue of $2.4M for the second quarter fiscal 2025 (Q2 FY25), +2% from a year earlier and -2% from the quarter before. Operating margin was -4.1%, net earnings $95K (3.9% of revenue).
Pharma-Bio Serv, Q2 FY25: revenue $2.4M (+2% year over year), operating margin -4.1%, net earnings $95K, operating cash flow −$302K. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.4M | -2% | +2% |
| Operating profit | −$98K | — | — |
| Net earnings | $95K | +492% | — |
| Operating cash flow | −$302K | -485% | — |
What changed
Revenue was $2.4M in Q2 FY25, up 2% year over year and down 2% from the previous quarter.
Gross margin was 33.9%, up 7.9 points from a year earlier. Operating costs exceeded revenue by $98K, an operating margin of -4.1%. Operating expenses fell 2% while revenue rose 2%. Net earnings were $95K. The effective tax rate was 5.5%. Non-operating items added $199K, 197% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$302K. Non-cash charges added back $19K of depreciation and amortization and $10K of share-based compensation. Working capital and other items used $426K. Capital expenditures of $4K exceeded it, leaving free cash flow of −$306K.
Questions
What was Pharma-Bio Serv's revenue in the second quarter fiscal 2025?
Pharma-Bio Serv (PBSV) reported revenue of $2.4M for the second quarter fiscal 2025 (Q2 FY25), +2% from a year earlier and -2% from the quarter before.
Was Pharma-Bio Serv profitable in the second quarter fiscal 2025?
Operating loss was $98K (-4.1% of revenue) and net earnings $95K.
Source: Pharma-Bio Serv 10-Q on SEC EDGAR.